AATK抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08201(CYP17A1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P08201(CYP17A1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The Apoptosis-Associated Tyrosine Kinase (AATK), also known as LMTK2 or BREK, is a serine/threonine kinase implicated in apoptosis, neuronal development, and cellular differentiation. Initially identified for its role in programmed cell death, AATK is highly expressed in the brain, particularly during neurogenesis, where it regulates neuronal migration, axon guidance, and synaptic plasticity. Its activity is modulated by autophosphorylation and interaction with signaling molecules like 14-3-3 proteins. AATK antibodies are essential tools for studying its expression, localization, and function in both physiological and pathological contexts.

Research links AATK to neurodegenerative diseases and cancer. In Alzheimer's and Parkinson’s, AATK dysfunction may contribute to neuronal death, while in cancers (e.g., leukemia, lung cancer), its downregulation is associated with impaired apoptosis and tumor progression. AATK antibodies enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding in elucidating its regulatory mechanisms and interactions.

Despite its established roles, AATK's full signaling network remains under investigation. Antibody specificity and cross-reactivity challenges require validation using knockout controls. Studies using AATK antibodies have highlighted its conserved function across mammals, emphasizing its potential as a therapeutic target. Ongoing research aims to clarify its dual roles in apoptosis and neurodevelopment, bridging gaps in understanding kinase-driven cellular decision-making.